Posts

U.S. Bodily Remedy (NYSE:USPH) Updates FY 2022 Earnings Steerage

U.S. Bodily Remedy (NYSE:USPH) Updates FY 2022 Earnings Steerage

U.S. Bodily Remedy (NYSE:USPH – Get Ranking) up to date its FY 2022 earnings steerage on Thursday. The corporate offered earnings per share steerage of $3.250-$3.350 for the interval, in comparison with the Thomson Reuters consensus earnings per share estimate of $3.330. The corporate issued income steerage of -.U.S. Bodily Remedy additionally up to date its FY22 steerage to $3.25-$3.35 EPS.

A number of equities analysis analysts have just lately commented on the corporate. TheStreet downgraded U.S. Bodily Remedy from a b- score to a c+ score in a report on Tuesday, November thirtieth. Zacks Funding Analysis raised U.S. Bodily Remedy from a maintain score to a purchase score and set a $102.00 value goal for the corporate in a report on Saturday, January eighth. Barrington Analysis reduce their value goal on U.S. Bodily Remedy from $144.00 to $123.00 in a report on Friday. Sidoti raised U.S. Bodily Remedy from a impartial score to a purchase score in a report on Monday, November twenty second. Lastly, CJS Securities raised U.S. Bodily Remedy from a market carry out score to an outperform score and set a $120.00 value goal for the corporate in a report on Tuesday, December 14th. 5 analysis analysts have rated the inventory with a purchase score, In accordance with MarketBeat, the inventory at the moment has a median score of Purchase and a consensus goal value of $120.00.

Shares of U.S. Bodily Remedy inventory opened at $91.06 on Friday. The corporate has a debt-to-equity ratio of 0.12, a present ratio of 0.97 and a fast ratio of 0.97. U.S. Bodily Remedy has a 1 yr low of $84.43 and a 1 yr excessive of $123.38. The corporate has a market capitalization of $1.18 billion, a price-to-earnings ratio of 38.42 and a beta of 1.41. The enterprise has a fifty day easy shifting common of $95.65 and a two-hundred day easy shifting common of $102.66.

Read Also:  Bluebird's adcomm sweep units stage for gene-therapy launches

U.S. Bodily Remedy (NYSE:USPH – Get Ranking) final issued its quarterly earnings information on Thursday, February twenty fourth. The corporate reported $0.72 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03. U.S. Bodily Remedy had a return on fairness of 16.63% and a web margin of 6.64%. The corporate had income of $129.83 million through the quarter, in comparison with analyst estimates of $128.62 million. Throughout the identical quarter within the earlier yr, the corporate posted $1.08 earnings per share. U.S. Bodily Remedy’s income was up 10.5% in comparison with the identical quarter final yr. As a gaggle, equities analysts anticipate that U.S. Bodily Remedy will publish 3.14 earnings per share for the present fiscal yr.

The corporate additionally just lately introduced a quarterly dividend, which shall be paid on Friday, April eighth. Traders of file on Monday, March 14th shall be given a $0.41 dividend. This is a rise from U.S. Bodily Remedy’s earlier quarterly dividend of $0.38. This represents a $1.64 dividend on an annualized foundation and a dividend yield of 1.80%. The ex-dividend date of this dividend is Friday, March eleventh. U.S. Bodily Remedy’s payout ratio is at the moment 64.14%.

In different U.S. Bodily Remedy information, CEO Christopher J. Studying offered 12,000 shares of the enterprise’s inventory in a transaction that occurred on Friday, December seventeenth. The inventory was offered at a median value of $93.89, for a complete transaction of $1,126,680.00. The sale was disclosed in a authorized submitting with the SEC, which might be accessed by means of this hyperlink. Additionally, COO Graham D. Reeve offered 1,000 shares of the enterprise’s inventory in a transaction that occurred on Monday, December sixth. The inventory was offered at a median value of $94.19, for a complete worth of $94,190.00. The disclosure for this sale might be discovered right here. 1.80% of the inventory is at the moment owned by insiders.

Read Also:  Oncolytic Virus Remedy Market Measurement, Share, Development Developments, Phase Evaluation by Area, Examine Overview and Forecast 2022-2025

A number of hedge funds and different institutional traders have just lately made modifications to their positions within the inventory. Millennium Administration LLC lifted its holdings in shares of U.S. Bodily Remedy by 666.8% through the 4th quarter. Millennium Administration LLC now owns 105,709 shares of the corporate’s inventory valued at $10,100,000 after buying a further 91,924 shares over the past quarter. Marshall Wace LLP bought a brand new stake in shares of U.S. Bodily Remedy through the 4th quarter valued at $5,142,000. Goldman Sachs Group Inc. lifted its holdings in shares of U.S. Bodily Remedy by 192.0% through the 4th quarter. Goldman Sachs Group Inc. now owns 54,406 shares of the corporate’s inventory valued at $5,199,000 after buying a further 35,771 shares over the past quarter. BlackRock Inc. lifted its holdings in shares of U.S. Bodily Remedy by 1.5% through the 4th quarter. BlackRock Inc. now owns 2,053,411 shares of the corporate’s inventory valued at $196,204,000 after buying a further 30,817 shares over the past quarter. Lastly, Cubist Systematic Methods LLC lifted its holdings in shares of U.S. Bodily Remedy by 564.9% through the 4th quarter. Cubist Systematic Methods LLC now owns 15,558 shares of the corporate’s inventory valued at $1,487,000 after buying a further 13,218 shares over the past quarter. Hedge funds and different institutional traders personal 97.93% of the corporate’s inventory.

About U.S. Bodily Remedy (Get Ranking)

U.S. Bodily Remedy, Inc operates outpatient bodily remedy clinics, which gives pre-and post-operative care and remedy for orthopedic-related problems, sports-related accidents, preventative care, rehabilitation of injured employees and neurological-related accidents. The corporate operates by means of the next segments: bodily remedy operations and industrial damage prevention companies.

Read Also:  Do Digital Remedy Packages Work?

See Additionally

Earnings History and Estimates for U.S. Physical Therapy (NYSE:USPH)

Need Extra Nice Investing Concepts?

Obtain Information & Rankings for U.S. Bodily Remedy Every day – Enter your e mail tackle beneath to obtain a concise day by day abstract of the newest information and analysts’ rankings for U.S. Bodily Remedy and associated firms with MarketBeat.com’s FREE day by day e mail publication.